On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


Sustainable Green Team, Ltd. (SGTM) Receives IPEMA Certification, Permitting Entry into Playground Surfacing Material Market Worth Approximately $4 Billion

  • SGTM received IPEMA certification through wholly-owned subsidiary Mulch Manufacturing
  • Certification permits entry into public playground surfacing material market worth approximately $4 billion, expected to grow to nearly $6 billion by 2026
  • High profits expected from busy hurricane season predicted to include 6 major hurricanes with winds of 111 mph or higher
  • First-quarter results include over $6.2 million in revenues, over $1.7 million gross profit

Sustainable Green Team (OTC: SGTM), a leading provider of solutions for tree and storm debris disposal, has just announced that it has received a certification from the International Play Equipment Manufacturers Association (“IPEMA”), allowing it to enter the lucrative public playground surfacing material market through its wholly-owned subsidiary, Mulch Manufacturing.

IPEMA is a non-profit membership and trade association that works to ensure that playground environments are safe from toxins and harmful chemicals. Through a set of environmental standards and compliance measures, IPEMA rewards suppliers with certifications attesting to the safety of their products.

The certification presents SGTM with another opportunity to fulfill its mission of keeping the environment sustainable and green through the creation of playground surfacing material made from trees broken during hurricanes that otherwise would have been destined for landfills. The public playground surfacing material market represents a new source of revenue to SGTM’s already diverse stream that includes tree removal, trimming, grapple hauling, land clearing, stump grinding, mulch processing, colorant production and packaging, transportation and distribution.

“This is a major achievement for us,” said SGTM CEO Tony Raynor in recent statements (http://ibn.fm/3kqDs). “We are now able to provide playground surfacing material through our manufactured recovered resources, further diversifying and increasing our revenue stream.”

SGTM’s impressive first-quarter financial results include revenues of over $6.2 million and gross profits of over $1.7 million (http://ibn.fm/aC1S5). These numbers are expected to grow further as the hurricane season gets underway with predictions including up to 6 major hurricanes with winds of 111 mph or higher (http://ibn.fm/dcWSt). Business activity following the IPEMA certification is expected to add considerable incremental revenue through access to the $4 billion playground surfacing materials market that is expected to increase to nearly $6 billion by 2026 (http://ibn.fm/htfXO).

SGTM operates with a mission of sustainability and commitment to the environment, prime motivating factors behind the company’s rebranding in July 2020 that included a name and ticker change from National Storm Recovery Inc. (OTC: NSRI) to Sustainable Green Team, Ltd. (OTC: SGTM). The company plans to continue driving its mission forward through synergistic and environmentally beneficial solutions to tree and storm waste disposal that transform waste into organic products for the benefit of its growing customer base, which includes governmental, residential, commercial and big-box clients.

To learn more about this company, view the investor presentation at http://ibn.fm/gms4i

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

From Our Blog

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”

September 25, 2020

CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second drug candidate, […]

Rotate your device 90° to view site.